Name
Clerio

ASV First Invested
December 2014

Status
Active

Location
Rochester, New York

Industry
Healthcare IT

Team
Mikael Totterman (Chairman)
Alex Zapesochny (CEO)
Scott Catlin (President)
Alexandra “Sasha” Latoya (Executive VP of Sales)
Hayley Russman (VP of Marketing)
Jay Baker, CPA (Chief Financial Officer)

Press
Democrat & Chronicle

Clerio is presently developing three products for the vision correction market: (i) a non-invasive, incision-free, tissue-sparing vision correction technology that modifies the refractive index of the cornea for the Intraocular Lens market, (ii) a premium contact lens targeted at an older demographic, and (iii) a non-invasive refractive surgery technology for the cornea that involves no cutting or ablation, distinguishing it from traditional LASIK surgery.

The Opportunity

Of the 43 million Americans who qualify for LASIK surgery each year, only 2% ever undergo the procedure. Most cite a fear of incisions or complications to the eye and high out-of-pocket costs. Many are not eligible for LASIK surgery. 

Clerio has developed a non-invasive alternative to LASIK that eliminates incisions in the eye, reducing the likelihood of complications. The technology is more precise than existing procedures, and allows refractive vision surgery to reach many more people. Additionally, the technology will be applied to intraocular lenses and hydrogel contact lenses, both of which will be more precisely customized to a patient’s prescription.